AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28572068 — intervention group
Group type: COMPARATOR
Intervention: Non-food TV show
Number of subjects: 0
Study 25884187 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention Hold on, for each other with personal support
Number of subjects: 0
Study 25884187 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention Hold on, for each other with automatic support
Number of subjects: 0
Study 25884187 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study 23322666 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg/day) for 12 weeks
Number of subjects: 27
Study 23322666 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D only (Control group)
Number of subjects: 27
Study 21293319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVT) 4 mg/0.1 mL
Number of subjects: 31
Study 21293319 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 mL
Number of subjects: 31
Study 18188512 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20-40 mg daily
Number of subjects: 57
Study 18188512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 18246740 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular dose of ceftriaxone (50 mg/kg, not exceeding 1 g)
Number of subjects: 104
Study 18246740 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day azithromycin (10 mg/kg on day 1, then 5 mg/kg daily on days 2-5)
Number of subjects: 104
Study 18246740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-day amoxicillin/clavulanate (90/6.4 mg/kg/day in 2 doses)
Number of subjects: 104
Study 18246740 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 104
Study 16194624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride patches (3mg per patch, 7.0 microg lisuride/h, applied every other day)
Number of subjects: 10
Study 16194624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15389177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity back school treatment
Number of subjects: 0
Study 15389177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity back school treatment
Number of subjects: 0
Study 15389177 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 11186094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg of brotizolam (BTZ) administered in the morning
Number of subjects: 9
Study 11186094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8622225 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal conjugate vaccine
Number of subjects: 90
Study 8622225 — intervention group
Group type: COMPARATOR
Intervention: Licensed meningococcal polysaccharide vaccine
Number of subjects: 90
Study 1449049 — intervention group
Group type: EXPERIMENTAL
Intervention: oral midazolam 0.45 mg/kg
Number of subjects: 123
Study 1449049 — intervention group
Group type: COMPARATOR
Intervention: Control group without premedication
Number of subjects: 123
Study 1449049 — intervention group
Group type: EXPERIMENTAL
Intervention: oral trimeprazine tartrate 2 mg/kg, methadone 0.1 mg/kg and droperidol 0.15 mg/kg
Number of subjects: 123
Study 1449049 — intervention group
Group type: EXPERIMENTAL
Intervention: intramuscular midazolam 0.15 mg/kg
Number of subjects: 123
Study 2578469 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 grams of aspirin daily
Number of subjects: 135
Study 2578469 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 grams of aspirin daily
Number of subjects: 135
Study 2578469 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression and low-molecular-weight dextran for three days
Number of subjects: 135
Study 2578469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran (less than 500 milliliters)
Number of subjects: 135
Study 2578469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran (more than 500 milliliters)
Number of subjects: 135
Study 30015577 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste
Number of subjects: 0
Study 30015577 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpowder
Number of subjects: 0
Study 30015577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash
Number of subjects: 0
Study 30015577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottled waters
Number of subjects: 0
Study 30015577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit juices
Number of subjects: 0
Study 30015577 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated sweet drinks and fruit juices
Number of subjects: 0
Study 28319589 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 97
Study 25956838 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 624
Study 25956838 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 624
Study 25956838 — intervention group
Group type: COMPARATOR
Intervention: Carbon Dioxide (CO2)
Number of subjects: 624
Study 25956838 — intervention group
Group type: COMPARATOR
Intervention: Water Immersion (WI)
Number of subjects: 624
Study 24268034 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (VSL#3, 900 × 10^9 daily)
Number of subjects: 18
Study 24268034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 18
Study 21972946 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum antiproteinuric treatment period
Number of subjects: 32
Study 21972946 — intervention group
Group type: COMPARATOR
Intervention: Placebo period
Number of subjects: 32
Study 21972946 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with overt proteinuria
Number of subjects: 32
Study 18035566 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Electroacupuncture (REA)
Number of subjects: 35
Study 18035566 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEA)
Number of subjects: 35
Study 17668012 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 17668012 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR and microarrays
Number of subjects: 0
Study 14600073 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg.kg(‐1).min(‐1) hydrocortisone infusion (II)
Number of subjects: 7
Study 14600073 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐microg bolus of GH (III)
Number of subjects: 7
Study 14600073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydrocortisone infusion (II) and GH (III) (IV)
Number of subjects: 7
Study 14600073 — intervention group
Group type: COMPARATOR
Intervention: NaCl (I)
Number of subjects: 7
Study 11726420 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled milrinone (0.25, 0.5, and 1 mg/mL)
Number of subjects: 20
Study 11726420 — intervention group
Group type: EXPERIMENTAL
Intervention: iPGI(2) (10 microg/mL)
Number of subjects: 20
Study 11726420 — intervention group
Group type: EXPERIMENTAL
Intervention: iPGI(2) (10 microg/mL) + inhaled milrinone (1 mg/mL)
Number of subjects: 20
Study 9221483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days followed by lansoprazole 30 mg q.d. for 14 days
Number of subjects: 50
Study 9221483 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days followed by omeprazole 20 mg q.d. for 14 days
Number of subjects: 50
Study 9221483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days
Number of subjects: 50
Study 9221483 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., bismuth-subcitrate 120 mg q.i.d., and lansoprazole 30 mg for 10 days)
Number of subjects: 50
Study 7960304 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction Scale (AS)
Number of subjects: 1257
Study 7960304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholism Scale (MAC)
Number of subjects: 1257
Study 3662908 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical epinephrine (1.25%) applied twice daily
Number of subjects: 22
Study 3662908 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin (0.5%) applied three times daily
Number of subjects: 22
Study 3662908 — intervention group
Group type: COMPARATOR
Intervention: Topical indomethacin placebo applied three times daily
Number of subjects: 22
Study 3662908 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical epinephrine (1.25%)
Number of subjects: 22
Study 29473482 — intervention group
Group type: EXPERIMENTAL
Intervention: PSTP
Number of subjects: 41
Study 29473482 — intervention group
Group type: COMPARATOR
Intervention: EDU
Number of subjects: 41
Study 27562221 — intervention group
Group type: EXPERIMENTAL
Intervention: Access therapy with PRF + 1% ALN
Number of subjects: 90
Study 27562221 — intervention group
Group type: COMPARATOR
Intervention: Access therapy with PRF
Number of subjects: 90
Study 27562221 — intervention group
Group type: COMPARATOR
Intervention: Access therapy alone
Number of subjects: 90
Study 25635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 µg)
Number of subjects: 652
Study 25635577 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 652
Study 23429555 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up formula supplemented with probiotics (Streptococcus thermophilus NCC 2496, Streptococcus salivarius DSM 13084, Lactobacillus rhamnosus LPR CGMCC 1.3724) and prebiotics (Raftilose/Raftiline)
Number of subjects: 224
Study 23429555 — intervention group
Group type: COMPARATOR
Intervention: Follow-up formula alone (placebo)
Number of subjects: 224
Study 23429555 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up formula supplemented with probiotics and prebiotics
Number of subjects: 224
Study 21367664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri‐plate
Number of subjects: 16
Study 18356546 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA + TCD + 2.8 mL microS (Target)
Number of subjects: 15
Study 18356546 — intervention group
Group type: COMPARATOR
Intervention: tPA + TCD (Control)
Number of subjects: 15
Study 17201276 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 0
Study 17201276 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy of cardiac insufficiency
Number of subjects: 0
Study 15268733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (4-8 ng/mL) plus Tacrolimus (8-12 ng/mL for 3 months, then 5-10 ng/mL)
Number of subjects: 87
Study 15268733 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus (8-16 ng/mL) plus Tacrolimus (3-8 ng/mL, with tacrolimus elimination from month 3)
Number of subjects: 87
Study 15268733 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus (8-16 ng/mL) plus Tacrolimus (3-8 ng/mL, with tacrolimus elimination from month 3) after protocol amendment
Number of subjects: 87
Study 11194595 — intervention group
Group type: COMPARATOR
Intervention: Short bursts (5 s) without treatment (group A)
Number of subjects: 80
Study 11194595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of propafenone 600 mg with short bursts (group B)
Number of subjects: 80
Study 11194595 — intervention group
Group type: COMPARATOR
Intervention: Prolonged bursts (30 s) without treatment (group C)
Number of subjects: 80
Study 11194595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of propafenone 600 mg with prolonged bursts (group D)
Number of subjects: 80
Study 8922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% in glucose 0.75%
Number of subjects: 120
Study 8922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% in glucose 7.5%
Number of subjects: 120
Study 8922770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% in glucose 7.5% with phenylephrine 0.125%
Number of subjects: 120
Study 1433591 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of bladder/sphincter dysfunction using a questionnaire
Number of subjects: 310
Study 1433591 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between bladder/sphincter dysfunction and urinary tract infections
Number of subjects: 310
Study 1433591 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between bladder/sphincter dysfunction and vesicoureteral reflux
Number of subjects: 310
Study 3933287 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFU (600 mg/day)
Number of subjects: 103
Study 3933287 — intervention group
Group type: COMPARATOR
Intervention: Tegafur (800 mg/day)
Number of subjects: 103
Study 3933287 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFU (in patients taking drugs for more than 90 days)
Number of subjects: 103
Study 3933287 — intervention group
Group type: COMPARATOR
Intervention: Tegafur (in patients taking drugs for more than 90 days)
Number of subjects: 103
Study 3933287 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFU
Number of subjects: 103
Study 3933287 — intervention group
Group type: COMPARATOR
Intervention: Tegafur
Number of subjects: 103
Study 31867637 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Cigarettes (VLNC; 0.4 mg nicotine/g tobacco)
Number of subjects: 752
Study 29680770 — intervention group
Group type: EXPERIMENTAL
Intervention: American clinicians' perceptions of a hypothetical White patient
Number of subjects: 164
Study 29680770 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal responsibility of the patient
Number of subjects: 164
Study 29680770 — intervention group
Group type: COMPARATOR
Intervention: French clinicians' perceptions
Number of subjects: 164
Study 27105704 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 95
Study 27105704 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 24859356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 733
Study 24859356 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin
Number of subjects: 733
Study 22471127 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy with Xiongbai Qianlie powder
Number of subjects: 72
Study 22471127 — intervention group
Group type: COMPARATOR
Intervention: Retention-enema with Ruyi Jinhuang powder plus millimeter-wave radiation
Number of subjects: 72
Study 22471127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 72
Study 20702745 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly MMN
Number of subjects: 324
Study 20702745 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly MMN
Number of subjects: 324
Study 20702745 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly IFA
Number of subjects: 324
Study 18248852 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective amobarbital procedures (ACA‐IAT)
Number of subjects: 17
Study 18248852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial SPECT co‐registrated to MRI
Number of subjects: 17
Study 18248852 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy
Number of subjects: 17
Study 16157616 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by general practitioners (GPs)
Number of subjects: 3186
Study 16157616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3186
Study 12814712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (n=1050)
Number of subjects: 2102
Study 12814712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=1052)
Number of subjects: 2102
Study 11534421 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) administered in continuous intravenous infusion
Number of subjects: 32
Study 11534421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - sodic dalteparine with dicumarinic afterwards
Number of subjects: 32
Study 9342997 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of medications
Number of subjects: 124
Study 8441870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal work rate cycling (60 rpm) at 60% TV̇E followed by sinusoidally varying work rate (30-90% of TV̇E)
Number of subjects: 19
Study 8441870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal work rate cycling
Number of subjects: 19
Study 3514688 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 3514688 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study 28913927 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic HA filler
Number of subjects: 72
Study 28913927 — intervention group
Group type: COMPARATOR
Intervention: Biphasic HA filler
Number of subjects: 72
Study 27592828 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐CRX-rich orange juice (125 mL, once a day, after breakfast)
Number of subjects: 20
Study 27592828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (β‐CRX removed from orange juice, 125 mL, once a day, after breakfast)
Number of subjects: 20
Study 24118703 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir plus peginterferon alfa-2b and ribavirin (BOC/PR)
Number of subjects: 2095
Study 24118703 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa-2b and ribavirin (PR)
Number of subjects: 2095
Study 24118703 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-guided therapy (RGT) with boceprevir plus peginterferon alfa-2b and ribavirin (BOC/PR)
Number of subjects: 2095
Study 24118703 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-guided therapy (RGT)
Number of subjects: 2095
Study 22085697 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin
Number of subjects: 16
Study 22085697 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin
Number of subjects: 16
Study 22085697 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone
Number of subjects: 16
Study 22085697 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin + 10 mg oxycodone
Number of subjects: 16
Study 22085697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21265311 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Motivational Interviewing (IMI)
Number of subjects: 0
Study 21265311 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Number of subjects: 0
Study 21265311 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance Abuse Awareness Seminar (SAAS)
Number of subjects: 0
Study 18275008 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly (n=21)
Number of subjects: 74
Study 18275008 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg once daily (n=23)
Number of subjects: 74
Study 18275008 — intervention group
Group type: COMPARATOR
Intervention: Control group (Osteopenia, n=30)
Number of subjects: 74
Study 18275008 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Risedronate, Teriparatide, Control)
Number of subjects: 74
Study 16682848 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week telephone and mail weight management intervention
Number of subjects: 26
Study 16682848 — intervention group
Group type: COMPARATOR
Intervention: Usual care intervention
Number of subjects: 26
Study 12552193 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip tube
Number of subjects: 80
Study 12552193 — intervention group
Group type: COMPARATOR
Intervention: Standard (Portex) 7.5-mm-ID endotracheal tube
Number of subjects: 80
Study 12064847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 6 sessions
Number of subjects: 145
Study 12064847 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (including pharmacological management and suggestions for aerobic fitness)
Number of subjects: 145
Study 12064847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBT and standard care)
Number of subjects: 145
Study 9952266 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (REM)
Number of subjects: 0
Study 9952266 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study 7490153 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lisinopril
Number of subjects: 143
Study 7490153 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lisinopril
Number of subjects: 143
Study 7490153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 2246421 — intervention group
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Number of subjects: 111
Study 2246421 — intervention group
Group type: COMPARATOR
Intervention: Nasotracheal intubation
Number of subjects: 111
Study 6458919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (40 micrograms in two puffs)
Number of subjects: 12
Study 6458919 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline capsules
Number of subjects: 12
Study 6458919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium + Theophylline
Number of subjects: 12
Study 6458919 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 12
Study 6436931 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg intravenously
Number of subjects: 2
Study 6436931 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA), indomethacin, noramidopyrine intravenously, and acetaminophen orally during a bronchospastic attack
Number of subjects: 2
Study 6436931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 2
Study 29848106 — intervention group
Group type: EXPERIMENTAL
Intervention: One Touch Verio™ (Verio) and OneTouch Verio Flex™ (Flex) with color range indicator (CRI)
Number of subjects: 163
Study 29848106 — intervention group
Group type: EXPERIMENTAL
Intervention: One Touch Verio™ (Verio) for T1D subjects
Number of subjects: 163
Study 29848106 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch Verio Flex™ (Flex) for T1D subjects
Number of subjects: 163
Study 29848106 — intervention group
Group type: COMPARATOR
Intervention: Control group (current BGM without color)
Number of subjects: 163
Study 29901926 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-cutting quadriceps sparing instruments
Number of subjects: 60